Opus Genetics, Inc. filed a Form 8-K on September 9, 2026, disclosing interim clinical data from Cohort 1 of its ongoing Phase 1/2 BIRD-1 trial of OPGx-BEST1 in patients with BEST1-related retinal diseases, along with updates on FDA interactions and Cohort 2 enrollment.
Key Highlights
- All five Cohort 1 participants demonstrated clinically meaningful improvement in visual function following treatment with OPGx-BEST1, according to the filing.
- No serious adverse events or dose-limiting toxicities were reported; all treatment-related adverse events were mild or moderate in severity.
- BCVA improved in 60% of participants (3/5), LLVA improved in 40% (2/5), and contrast sensitivity improved in 40% (2/5).
- Structural improvements were observed in four of five participants, with reductions in vitelliform material in 67% of BVMD participants (2/3) and reductions in intraretinal fluid in 100% of ARB participants (2/2).
- Cohort 2 has been over-enrolled with eight participants, evaluating OPGx-BEST1 at 4.5 x 10⁹ vg/eye, with dosing expected to be complete in the fourth quarter of 2026.
- The company aligned with the FDA on a potential pivotal endpoint based on a microperimetry improvement of at least 3 dB in at least 5 prespecified loci, combined with a patient-reported outcome in a randomized, controlled trial.
- New epidemiology research cited in the filing estimates approximately 23,600 symptomatic BEST1 patients in the U.S. and approximately 45,400 symptomatic BEST1 patients globally.
Opus Genetics Discloses BIRD-1 Cohort 1 Results and FDA Alignment on OPGx-BEST1
Trading on NASDAQ:IRD, Opus Genetics reported that Cohort 1 of its BIRD-1 Phase 1/2 clinical trial enrolled five participants treated at 1.5 x 10⁹ vg/eye: three participants with best vitelliform macular dystrophy (BVMD) who have reached three months of follow-up, and two participants with autosomal recessive bestrophinopathy (ARB) who have reached six months of follow-up. According to the filing, all five participants showed clinically meaningful improvement in visual function, measured across best-corrected visual acuity, low-luminance visual acuity, contrast sensitivity, and microperimetry.
The filing states that among evaluable participants, 75% (3/4) demonstrated clinically meaningful improvement in retinal sensitivity by microperimetry. The company disclosed that these gains were "concentrated in the treated retinal pigment epithelial Transitional Zone, where viable photoreceptors remain, with the greatest functional improvements observed in participants with less advanced disease." Structural improvements included reductions in vitelliform material in 67% of BVMD participants (2/3) and reductions in intraretinal fluid in 100% of ARB participants (2/2). The third BVMD participant had "possible, but not definitive, reduction in vitelliform material," according to the filing.
The company reported that, based on Cohort 1 findings, it has advanced to the higher-dose Cohort 2, which originally designed to enroll five participants has been over-enrolled with eight participants, most of whom have BVMD. Topline three-month data from Cohort 2 are expected in the second quarter of 2027, according to the filing. The company also disclosed that in August 2026 it met with the FDA, aligning on Phase 3 and commercial manufacturing requirements expected to be completed in early 2027, with participant dosing in a Phase 3 trial expected to begin planning in 2027. The filing cautions that these are forward-looking statements based on management's current expectations and subject to risks and uncertainties, and that the clinical trial data are interim and subject to change.
What Was Disclosed
Opus Genetics filed an 8-K on September 9, 2026, furnishing interim Phase 1/2 clinical trial results for OPGx-BEST1 in BEST1-related retinal disease, reporting on safety, efficacy outcomes, Cohort 2 enrollment, and FDA alignment on pivotal trial endpoints and manufacturing requirements.




Please wait processing your request...